FIELD: medicine.
SUBSTANCE: invention relates to the field of medicine, namely to ophthalmology, and is intended for treating a non-exudative form of age-related macular degeneration (AMD) in elderly patients. Along with administration of antioxidants and lutein-containing preparations, aquadetrim and bilobil forte are used orally for 5 to 6 months with monthly monitoring of blood biochemical indicators to eliminate cases of vitamin D overdose.
EFFECT: provides a possibility of inhibiting the progression of the "dry" form of AMD in elderly patients, as confirmed by an improvement in most indicators of the ophthalmological status and local blood flow, a reduction in the pro-inflammatory activity of cytokines, an increase in the anti-inflammatory activity of cytokines, and reliable associations of total vitamin D with maximally corrected visual acuity, visual acuity without correction, visual field, and visocontrastometry.
1 cl, 2 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR SELECTING THERAPEUTIC APPROACH TO AGE-RELATED MACULAR DEGENERATION (AMD) | 2018 |
|
RU2707955C1 |
METHOD FOR DETERMINING INDICATIONS FOR ANTIANGIOGENIC THERAPY IN CASE OF SUSPICION OF WET FORM OF AGE-RELATED MACULAR DEGENERATION | 2021 |
|
RU2758662C1 |
METHOD FOR PREDICTING THE EFFECTIVENESS OF TREATMENT OF NEOVASCULAR FORM OF AMD | 2022 |
|
RU2788103C1 |
METHOD OF TREATING "DRY" FORM OF AGE-RELATED MACULAR DEGENERATION | 2012 |
|
RU2489146C1 |
METHOD OF TREATING MACULAR OEDEMAS OF VARIOUS GENESES | 2009 |
|
RU2393824C1 |
METHOD OF TREATING "DRY" FORM OF AGE MACULAR DEGENERATION | 2008 |
|
RU2375016C1 |
USE OF CABERGOLINE IN TREATING PATHOLOGICAL CONDITIONS CAUSED BY HIGH LEVELS OF THE VASCULAR ENDOTHELIAL GROWTH FACTOR | 2016 |
|
RU2698728C1 |
METHOD OF TREATING EARLY STAGES OF AGE-RELATED MACULAR DEGENERATION | 2021 |
|
RU2776695C1 |
METHOD TO TREAT "DRY" FORM OF AGE MACULAR DEGENERATION | 2007 |
|
RU2333737C1 |
METHOD FOR DETERMINING THE PRO-INFLAMMATORY AND ANTI-INFLAMMATORY INTERLEUKINS IN THE ANTERIOR CHAMBER OF THE EYE IN THE PATIENTS WITH PRESENILE CATARACT OF THE EYE FOR DIAGNOSING THE POSTOPERATIVE COMPLICATIONS | 2018 |
|
RU2702735C1 |
Authors
Dates
2021-09-22—Published
2020-09-22—Filed